Table 1.
Cancer | TPPP | Level | Level | Other | |
---|---|---|---|---|---|
Pancreatic | TPPP/p25 | Protein | Low | High level helps invasion | [74] |
Pancreatic | TPPP/p25 | RNA | Low | [71] | |
Pancreatic | TPPP/p25 | RNA | Low | [72] | |
Liver | TPPP/p25 | RNA | Low | [73] | |
Oligodendroglioma | TPPP/p25 | Protein | Low | [70] | |
Lung | TPPP/p25 | RNA | Low | 5p15.33 | [75] |
non-small cell Lung | TPPP/p25 | DNA | gain of 5p15.33 | [76] | |
Bile duct | TPPP/p25 | DNA | gain of 5p15.33 | [77] | |
Bladder | TPPP/p25 | DNA | gain of 5p15.33 | [78] | |
HeLa cells | TPPP3 | RNA | Depletion by RNAi suppressed cell proliferation | [79] | |
Lung (Lewis carcinoma) | TPPP3 | RNA | Depletion by RNAi inhibits tumor cell growth | [80] | |
Colorectal | TPPP3 | RNA, Protein | High | Knockdown inhibited cell proliferation, migration and invasion; overall survival rate was lower in patients with high expression of TPPP3 | [81] |
non-small cell Lung | TPPP3 | Protein | High | Knockdown by shRNA inhibited cell proliferation in vitro; depletion of TPPP3 inhibited lung cancer growth in vivo | [82] |
Lung | TPPP3 | Protein | High | [83] | |
Ovarian | TPPP3 | RNA | High | 10x overexpression | [84] |
Clear cell sarcoma | TPPP3 | RNA, Protein | High | [85] | |
Pancreatic ductal adenocarcinoma | TPPP3 | Protein | Higher TPPP3 level indicates long survival | [86] |